Post by
palinc2000 on Jul 14, 2022 7:57am
Second Quarter
mixed bag.... Reduced top end of guidance by 2 Million due to Europe in spite if having said on April 27 that the decision to stop selling in Europe would not affect the previously issued sales guidance..
-Patients complaints with Egrifta seems to be resolved but requires additional studies($$)
-F8 -- delayed again ... means also longer pause for Nash
Nash still in the plans
Comment by
palinc2000 on Jul 14, 2022 8:02am
I like the reference to the VAMOS study